

Michael B Nichol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9570092/publications.pdf>

Version: 2024-02-01

74
papers

3,358
citations

172207

29
h-index

143772

57
g-index

74
all docs

74
docs citations

74
times ranked

4093
citing authors

#	ARTICLE	IF	CITATIONS
1	A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases. <i>Value in Health</i> , 2007, 10, 3-12.	0.1	534
2	Patient-reported reasons for discontinuing overactive bladder medication. <i>BJU International</i> , 2010, 105, 1276-1282.	1.3	336
3	Medication Adherence and Associated Hemoglobin A1c in Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1357-1362.	0.9	248
4	Persistence and Adherence of Medications for Chronic Overactive Bladder/Urinary Incontinence in the California Medicaid Program. <i>Value in Health</i> , 2005, 8, 495-505.	0.1	171
5	The Costs of Interrupting Antihypertensive Drug Therapy in a Medicaid Population. <i>Medical Care</i> , 1994, 32, 214-226.	1.1	169
6	Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer. <i>Value in Health</i> , 2009, 12, 124-129.	0.1	163
7	A Critical Evaluation of the Methodology of the Literature on Medication Compliance. <i>Annals of Pharmacotherapy</i> , 1999, 33, 531-540.	0.9	102
8	Compliance with Sulfonylureas in a Health Maintenance Organization: A Pharmacy Record-Based Study. <i>Annals of Pharmacotherapy</i> , 1999, 33, 281-288.	0.9	95
9	Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. <i>Journal of Medical Economics</i> , 2015, 18, 457-465.	1.0	87
10	The Clinical and Economic Burden of Nonadherence with Antihypertensive and Lipid-Lowering Therapy in Hypertensive Patients. <i>Value in Health</i> , 2009, 12, 489-497.	0.1	70
11	Evaluating Use Patterns of and Adherence to Medications for Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2009, 181, 2214-2222.	0.2	58
12	Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. <i>Vascular Health and Risk Management</i> , 2008, 4, 673-81.	1.0	54
13	Quality of Anticoagulation Monitoring in Nonvalvular Atrial Fibrillation Patients: Comparison of Anticoagulation Clinic versus Usual Care. <i>Annals of Pharmacotherapy</i> , 2008, 42, 62-70.	0.9	48
14	The Impact of Value-Based Benefit Design on Adherence to Diabetes Medications: A Propensity Score-Weighted Difference in Difference Evaluation. <i>Value in Health</i> , 2010, 13, 846-852.	0.1	47
15	Mapping the SF-12 to the HUI3 and VAS in a Managed Care Population. <i>Medical Care</i> , 2004, 42, 927-937.	1.1	45
16	Multiple Medication Adherence and its Effect on Clinical Outcomes Among Patients With Comorbid Type 2 Diabetes and Hypertension. <i>Medical Care</i> , 2013, 51, 879-887.	1.1	44
17	Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population. <i>Head and Neck</i> , 2008, 30, 178-186.	0.9	43
18	Medication Use in Residential Care Facilities for the Elderly. <i>Annals of Pharmacotherapy</i> , 1999, 33, 149-155.	0.9	42

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of Prostate Health Index for prostate cancer detection. <i>BJU International</i> , 2012, 110, 353-362.	1.3	41
20	Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status. <i>American Journal of Hematology</i> , 2015, 90, S11-6.	2.0	41
21	Estimating the Effect of Medication Adherence on Health Outcomes among Patients with Type 2 Diabetes—An Application of Marginal Structural Models. <i>Value in Health</i> , 2010, 13, 1038-1045.	0.1	38
22	The demand for statin: the effect of copay on utilization and compliance. <i>Health Economics (United Kingdom)</i> , 2008, 28, 107-120.	0.8	33
23	A framework for planning and critiquing medication compliance and persistence research using prospective study designs. <i>Clinical Therapeutics</i> , 2009, 31, 421-435.	1.1	33
24	Antipsychotic Drug Use Patterns and the Cost of Treating Schizophrenia. <i>Psychiatric Services</i> , 2000, 51, 525-527.	1.1	32
25	Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2013, 65, 299-303.	1.5	32
26	The Kaiser Permanente/USC Patient Consultation Study: Change in use and cost of health care services. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 2485-2499.	0.5	31
27	The Effects of Consultation on Over-the-Counter Medication Purchasing Decisions. <i>Medical Care</i> , 1992, 30, 989-1003.	1.1	30
28	Transitioning the Second-Generation Antihistamines to Over-the-Counter Status. <i>Medical Care</i> , 2003, 41, 1382-1395.	1.1	30
29	The Impact of Change in Visual Field on Health-Related Quality of Life. <i>Ophthalmology</i> , 2011, 118, 1310-1317.	2.5	29
30	Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 253-261.	2.0	29
31	Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates. <i>Value in Health</i> , 2017, 20, 1074-1082.	0.1	29
32	The Role of SSRI Antidepressants for Treating Depressed Patients in the California Medicaid (Medi-Cal) Program. <i>Value in Health</i> , 1999, 2, 269-280.	0.1	24
33	Measuring the Effects of Medication Use on Health-Related Quality of Life in Patients with Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 1999, 16, 433-448.	1.7	24
34	Physical activity and health outcomes in persons with haemophilia B. <i>Haemophilia</i> , 2014, 20, 814-821.	1.0	24
35	Nonadherence to clinical practice guidelines and medications for multiple chronic conditions in a California Medicaid population. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2010, 50, 496-507.	0.7	22
36	Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. <i>BJU International</i> , 2013, 111, 1245-1252.	1.3	22

#	ARTICLE	IF	CITATIONS
37	Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence. <i>Clinical Therapeutics</i> , 2008, 30, 761-774.	1.1	21
38	Transition Probabilities and Predictors of Adherence in a California Medicaid Population Using Antihypertensive and Lipid-Lowering Medications. <i>Value in Health</i> , 2009, 12, 544-550.	0.1	21
39	The Increased Cost of Medical Services for People Diagnosed With Primary Open-Angle Glaucoma: A Decision Analytic Approach. <i>American Journal of Ophthalmology</i> , 2010, 150, 74-81.	1.7	21
40	Utilization Patterns of Antidepressant Medications in a Patient Population Served by a Primary Care Medical Group. <i>Journal of Managed Care Pharmacy</i> , 1999, 5, 243-249.	2.2	20
41	Generic and therapeutic statin switches and disruptions in therapy. <i>Current Medical Research and Opinion</i> , 2009, 25, 1247-1260.	0.9	20
42	Pharmacy-Enforced Outpatient Drug Treatment Protocols: A Case Study of Medi-Cal Restrictions for Cefaclor. <i>Annals of Pharmacotherapy</i> , 1993, 27, 155-161.	0.9	19
43	Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser permanente/USC patient consultation study. <i>Clinical Therapeutics</i> , 1995, 17, 1188-1206.	1.1	19
44	Longitudinal Changes in Health-Related Quality of Life for Chronic Diseases: An Example in Hemophilia A. <i>Journal of General Internal Medicine</i> , 2014, 29, 760-766.	1.3	18
45	Eligibility, utilization, and costs in a California Medicaid lupus population. <i>Arthritis and Rheumatism</i> , 2004, 51, 996-1003.	6.7	17
46	Public Members on Occupational Licensing Boards: Effects on Legislative Regulatory Reforms. <i>Southern Economic Journal</i> , 1989, 55, 610.	1.3	16
47	Depression and health-related quality of life in patients with rheumatoid arthritis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 645-653.	0.7	16
48	Non-severe haemophilia: Is it benign? Insights from the PROBE study. <i>Haemophilia</i> , 2021, 27, 17-24.	1.0	16
49	Cost-Benefit Analysis of First-Generation Antihistamines in the Treatment of Allergic Rhinitis. <i>Pharmacoeconomics</i> , 2004, 22, 929-942.	1.7	15
50	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. <i>BMJ Open</i> , 2018, 8, e021900.	0.8	15
51	Consumer Knowledge of Over-the-Counter Phenazopyridine. <i>Annals of Family Medicine</i> , 2004, 2, 240-244.	0.9	14
52	The Economic Impact of Payer Policies after the Rx-to-OTC Switch of Second-Generation Antihistamines* *Preliminary results of this analysis were presented at the 9th annual HMO Research Network Conference April 1-2, 2003. <i>Value in Health</i> , 2004, 7, 402-412.	0.1	14
53	Inside the Black Box: The Case Review Process of an Elder Abuse Forensic Center. <i>Gerontologist</i> , The, 2016, 56, 772-781.	2.3	14
54	Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. <i>Haemophilia</i> , 2019, 25, 75-83.	1.0	14

#	ARTICLE	IF	CITATIONS
55	Usage patterns of over-the-counter phenazopyridine (pyridium). <i>Journal of General Internal Medicine</i> , 2003, 18, 281-287.	1.3	13
56	Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk. <i>Value in Health</i> , 2006, 9, 361-368.	0.1	13
57	Opinions Regarding the Academy of Managed Care Pharmacy Dossier Submission Guidelines: Results of a Small Survey of Managed Care Organizations and Pharmaceutical Manufacturers. <i>Journal of Managed Care Pharmacy</i> , 2007, 13, 360-371.	2.2	13
58	Separating gains and losses in health when calculating the minimum important difference for mapped utility measures. <i>Quality of Life Research</i> , 2008, 17, 955-961.	1.5	13
59	Prevalence and incidence of adult attention deficit/hyperactivity disorder in a large managed care population. <i>Current Medical Research and Opinion</i> , 2014, 30, 1291-1299.	0.9	13
60	Critical Analysis of the Content and Enforcement of Mandatory Consultation and Patient Profile Laws. <i>Annals of Pharmacotherapy</i> , 1992, 26, 1149-1155.	0.9	11
61	Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. <i>Haemophilia</i> , 2019, 25, 365-372.	1.0	11
62	Structural Reforms and Licensing Board Performance. <i>American Politics Research</i> , 1990, 18, 376-400.	0.7	9
63	Impact of Mental Health Comorbidities on Health Care Utilization and Expenditure in a Large US Managed Care Adult Population with ADHD. <i>Value in Health</i> , 2014, 17, 661-668.	0.1	9
64	An economic analysis of antimicrobial prophylaxis against urinary tract infection in patients undergoing transurethral resection of the prostate. <i>Clinical Therapeutics</i> , 1999, 21, 1589-1603.	1.1	8
65	Is pharmacy's vision of the future too narrow?. <i>American Journal of Health-System Pharmacy</i> , 1995, 52, 1208-1214.	0.5	7
66	The Impact of an Over-the-Counter Migraine Medication Program on Quality of Life. <i>Headache</i> , 2003, 43, 191-201.	1.8	7
67	The Use of First- and Second-Line Outpatient Antibiotics Under the Saskatchewan Drug Plan. <i>Pharmacoeconomics</i> , 1995, 7, 543-554.	1.7	5
68	PSY11 ESTIMATION OF CAUSAL EFFECTS OF PHYSICAL ACTIVITY ON OBESITY BY A RECURSIVE BIVARIATE PROBIT MODEL. <i>Value in Health</i> , 2009, 12, A131-A132.	0.1	5
69	INCREMENTAL EXPENDITURE OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC TREATMENT USING INSTRUMENTAL VARIABLES IN PANEL DATA. <i>Health Economics (United Kingdom)</i> , 2013, 22, 807-823.	0.8	4
70	AD4: A TIME-VARYING SURVIVAL MODEL FOR THE ASSOCIATION OF ADHERENCE WITH HMG-COA INHIBITORS TO THE RISK OF ADVERSE EVENTS. <i>Value in Health</i> , 2003, 6, 191-192.	0.1	2
71	The Role of Outcomes Research in Defining and Measuring Value in Benefit Decision. <i>Journal of Managed Care Pharmacy</i> , 2006, 12, S19-S23.	2.2	2
72	Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia's Hematology Utilization Group Study Part VII (HUGS VII). <i>Journal of Blood Medicine</i> , 2022, Volume 13, 229-241.	0.7	2

#	ARTICLE	IF	CITATIONS
73	Adalimumab for Rheumatoid Arthritis. <i>Disease Management and Health Outcomes</i> , 2004, 12, 1-8.	0.3	1
74	Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model. <i>Health Services and Outcomes Research Methodology</i> , 2018, 18, 75-95.	0.8	0